REGENXBIO Inc.

For the period ended Dec 31, 2025. Filed Mar 5, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 5, 2026

RGNX$8.07+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 5, 2026.

REGENXBIO INC.
By:	/s/ Curran Simpson
	Curran SimpsonPresident and Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Kenneth T. Mills
Signature	Title	Date
/s/ Curran Simpson	President, Chief Executive Officer and	March 5, 2026
Curran Simpson	Director (Principal Executive Officer)
/s/ Mitchell Chan	Chief Financial Officer	March 5, 2026
Mitchell Chan	(Principal Financial and Accounting Officer)
/s/ Kenneth T. Mills	Chairman of the Board of Directors	March 5, 2026
/s/ Jean Bennett	Director	March 5, 2026
Jean Bennett
/s/ Allan M. Fox	Director	March 5, 2026
Allan M. Fox
/s/ Alexandra Glucksmann	Director	March 5, 2026
Alexandra Glucksmann
/s/ A.N. “Jerry” Karabelas	Director	March 5, 2026
A.N. “Jerry” Karabelas
/s/ George Migausky	Director	March 5, 2026
George Migausky
/s/ David C. Stump	Director	March 5, 2026
David C. Stump
/s/ Daniel Tassé	Director	March 5, 2026
Daniel Tassé
/s/ Jennifer Zachary	Director	March 5, 2026
Jennifer Zachary

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.